FGFR4 and diabetic cardiomyopathy: Whether or not FGF21-FGFR4 signaling will prove to be a successful target for intervention against diabetic cardiomyopathy, the observation that FGF21 promotes concentric cardiac hypertrophy should be considered by the community actively developing FGF21 analogs and mimetics as agents to promote weight loss, hyperglycemia and dyslipidemia8.